Dr. Wiebe is a transplant nephrologist with expertise in immunogenetics and the development of de novo donor-specific antibodies in renal transplantation. He has published on the clinical and pathologic risk factors for de novo donor-specific antibody development. He also has developed expertise in the quantification and identification of the HLA alloepitopes mismatched between donor and recipient HLA alleles and has published on the role these play as predictors of de novo donor-specific antibody (dnDSA) development, T cell-mediated rejection (TCMR), and antibody-mediated rejection (ABMR).

Ongoing work investigates the potential for HLA molecular mismatch to serve as a predictive and prognostic biomarker in renal transplantation. In addition, recent publications include the importance of recurrent/subsequent TCMR and the correlation between first or second TCMR events and allograft survival. As an invited member of the Sensitization in Transplant: Assessment of Risk (STAR) expert working group Dr. Wiebe has been involved in two consensus publications and is a co-leader and speaker for the non-HLA Ab working group.